Eliem Therapeutics Inc

NASDAQ ELYM

Data sourced from

and

Download Data

Eliem Therapeutics Inc Shareholders' Equity 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 28.95%

Eliem Therapeutics Inc Shareholders' Equity 3 year CAGR is 28.95% for the Trailing 12 Months (TTM) ending March 31, 2024. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Eliem Therapeutics Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 116.86 M, a -24.68% change year over year.
Eliem Therapeutics Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 155.14 M, a 212.69% change year over year.
Eliem Therapeutics Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 49.62 M.

NASDAQ: ELYM

Eliem Therapeutics Inc

CEO	Mr. Robert W. Azelby M.B.A.
IPO Date	Aug. 10, 2021
Location	United States
Headquarters	23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees	9
Sector	Healthcare
Industry	Biotechnology

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key trends